Does Mounjaro Stop Working — or Is Something Else Going On?

The difference between slowing down and actually stopping

Plateau is the word most people reach for, and it's worth being precise about what it means. Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) which reduce appetite, slow gastric emptying, and shift how the body handles blood sugar. That mechanism stays active as long as you're injecting. What changes over months is not the medicine's activity but your body's response to being in a sustained calorie deficit.

As weight falls, your resting energy needs fall with it. The same eating habits that produced a deficit at 100 kg produce a smaller one at 85 kg. That arithmetic (not a fading drug) accounts for most apparent plateaux. Separately, some people find their appetite gradually edges back toward old patterns as the novelty of a new routine wears off. The NHS's patient information on tirzepatide is clear that the medicine is intended to work alongside sustained dietary and activity changes, not instead of them.

For people wondering whether what they're experiencing is a true plateau or something about why Mounjaro seems to lose its effect over time, it's worth reading what the trial data actually show before drawing conclusions. The short version: in SURMOUNT-1, weight loss continued across 72 weeks at the top maintenance dose. It didn't reverse. It did slow.

The dose question, and why it matters more than most people realise

Tirzepatide starts at 2.5 mg because that dose is designed to settle your system, not deliver the full clinical effect. The therapeutic work happens at higher doses (typically 10 mg or 15 mg) reached gradually over several months. If you're on 5 mg and progress has stalled, the answer may simply be that you haven't yet reached the dose where the medicine does most of its job.

Dose titration is a prescriber's decision, not something to self-manage. At our pharmacy, a GPhC-registered prescriber reviews every repeat order, someone who can look at your weight trajectory, how you're tolerating the current strength, and whether the next step makes clinical sense. That review happens before every dispatch, not just at the start.

It is also worth knowing that if less than 5% weight loss has occurred after 6 months at the highest tolerated dose, NICE's technology appraisal for tirzepatide (TA1026) recommends reviewing whether continuing is appropriate. That is a clinical checkpoint, not a rejection, it means talking to your prescriber, not stopping immediately.

The cost of treatment can feel like an added pressure here. If you want to understand what influences Mounjaro's UK pricing, that page explains the context, including Eli Lilly's 2025 price increase and what private providers typically include.

What the evidence says about long-term use and whether Mounjaro can stop working

The question of whether tirzepatide can genuinely stop working (as opposed to producing a slower rate of loss) has a reasonably clear answer from trial data. Participants who discontinued the medicine after 72 weeks regained a significant proportion of lost weight, which tells you the drug was still doing something while they were on it. Stopping produces regain; that is the opposite of ineffectiveness.

Whether that means lifelong treatment is right for any individual is a genuinely open clinical question, and one covered in more detail on the page about whether tirzepatide stops working over longer periods. Our clinical team reviews the emerging evidence regularly and reflects it in prescribing decisions.

There is also a specific question some people ask about interactions, and if you have recently given birth you may want to read about using Mounjaro postpartum before starting or resuming treatment. Separately, for those using hormonal contraception, whether Mounjaro stops the pill from working is a concern that has a clear, answered explanation worth checking. If you are simply asking about absorption timing, the effect of Mounjaro on the pill is also covered separately.

The honest conversation to have with your prescriber

If your progress has genuinely slowed and you're not sure why, a prescriber is the right person to talk to, not a forum, not a supplement. The things worth raising: how closely your eating has tracked what you planned, whether your activity level has changed, any new health factors, and how you're tolerating the current dose. Any of those could shift the picture.

You might also consider whether your expectations are calibrated to the evidence. Clinical trials show meaningful average reductions over 72 weeks, but individual results vary. Some people lose more, some less. A month with no movement on the scales is not the same as Mounjaro having stopped working.

If you're at an earlier stage and still deciding whether treatment is right for you, the free consultation with our prescribers is the place to start. There's no obligation; it's a clinical conversation, and it happens the same day you submit your details. Check your eligibility and see whether tirzepatide or another option fits your situation.